CA9 and nonpapillary renal cell carcinoma: A recent molecular imaging tool targeting CAIX is girentuximab [40], also called cG250, an anti-CAIX chimeric antibody which allows PET/CT imaging when bonded with certain isotopes (131I, 124I or 111In) that furthermore leads a pathway to radioimmunotherapy (RIT) in ccRCC.